Skip to main content

Table 2 Top 20 therapeutic target genes overexpressed in ACP compared to normal brain tissues and a variety of CNS and peripheral malignancies

From: Identification of targets for rational pharmacological therapy in childhood craniopharyngioma

Symbol Gene name Average percentile # of ACP >66th %-ile Therapeutic agents Fold p-Value
MMP12 matrix metallopeptidase 12 99.4 15 AZD1236 820 3.03E-49
SHH sonic hedgehog homolog 98.9 15 Erismodegib, Vismodegib 96.8 1.48E-48
IL2RB interleukin 2 receptor, beta 96.7 15 Denileukin diftitox 12.4 4.87E-23
LCK lymphocyte-specific protein tyrosine kinase 95.2 15 Dasatinib, Pazopanib 5.50 8.24E-16
EPHA2 EPH receptor A2 95.1 15 Dasatinib, Regorafenib 16.6 6.8E-16
AREG Amphiregulin 93.9 15 Cetuximab 20.8 4.82E-17
PIK3CD phosphoinositide-3-kinase, catalytic, delta 93.8 15 Idelalisib 6.79 3.55E-10
IL6R interleukin 6 receptor 91.9 15 Siltuximab 6.13 7.06E-8
MMP9 matrix metallopeptidase 9 91.6 15 AZD1236 41.0 9.79E-14
EPCAM epithelial cell adhesion molecule 90.7 15 Tucotuzumab celmoleukin 87.4 2.01E-11
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 89.9 15 Bosutinib, Dasatinib 2.47 3.71e-7
MUC1 mucin 1 89.3 15 HuHMFG1 6.30 1.27E-7
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 86.7 15 Lapatinib 22.8 4.19E-08
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 91.7 14 Denosumab 5.17 4.28E-8
MAPK14 mitogen-activated protein kinase 14 91.3 14 Regorafenib 2.65 2.49E-8
PTGS2 prostaglandin-endoperoxide synthase 2 85.6 14 Lenalidomide 10.5 9.23E-7
RRAS related RAS viral (r-ras) oncogene homolog 85.4 14 Sorafenib 3.61 2.32E-5
PSMB1 proteasome (prosome, macropain) subunit, beta type, 1 83.8 14 Carfilzomib 1.45 5.85E-5
EGFR epidermal growth factor receptor 83.4 14 Cetuximab, Erlotinib, Gefitinib, Lapatinib, etc. 7.57 5.99E-05
CD52 CD52 molecule 86.3 13 Alemtuzumab 8.85 4.51E-12